Lipid formulations of amphotericin B

Current Clinical Topics in Infectious Diseases

Volumn , Issue 20, 2000, Pages 1-23

  Dix, Suzanne P ^a   Andriole, Vincent T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; LIPOSOME;

COST; ECONOMICS; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; PHARMACOECONOMICS; PYREXIA IDIOPATHICA; REVIEW;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEVER OF UNKNOWN ORIGIN; HUMANS; IMMUNOCOMPROMISED HOST; LIPOSOMES; MYCOSES;

EID: 0034565512     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (55)

1. Saral R. Candida and aspergillosis infections in immunocompromised patients: an overview. J Infect Dis 1991;13:487-492.
2. Walsh TJ, Pizzo PA. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988;7:460-475.
3. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl 20): 133S-144S.
4. Bangham AD. Liposomes: realizing their promise. Hosp Pract Off Ed 1992;27:51-56, 61-62.
5. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-618.
6. Walsh TJ, Hiemenz J. Lipid formulations of amphotericin B: recent developments in improving the therapeutic index of a gold standard. Infect Dis Clin Pract 1998;7(suppl 1):S16-S27.
7. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-1587.
8. Wasan KM, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 1996;23:1126-1138.
9. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;544:590-597.
10. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107:271-282.
11. Janknegt R, deMarie S, Bakker-Woudenbert IA, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-291.
12. DeMarie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10(suppl 2):S93-S96.
13. Juliano RL, Grant CW, Barber KR, et al. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987;31:1-11.
14. Abelcet product information. The Liposome Company, Princeton, NJ, May 1998.
15. Data on file. The Liposome Company, Princeton, NJ.
16. Dix SP. Pharmacology of lipid formulations of amphotericin B. Infect Dis Clin Pract 1998; 7(suppl 1):S8-S15.
17. Amphotec product information. Sequus Pharniaceuticals, Menlo Park, CA, October 1996.
18. Data on file. Sequus Pharmaceuticals, Menlo Park, CA.
19. Adler-Moore JP, Profitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3:429-450.
20. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-276.
21. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1985;152:1037-1043.
22. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988;7: 424-438.
23. Morgan DJ, Ching MS, Raymond K, et al. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983;34: 248-253.
24. Heinemann V, Kahny B, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994;14(suppl 1):8S-9S.
25. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
26. Walsh TJ, Heimenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.
27. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;20:39-43.
28. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-1153.
29. Bowden RA, Cays M, Gooley T, et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173: 1208-1215.
30. Noskin G, Pietrelli L, Gurwith M, et al. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999;23:697-703.
31. Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haem 1994;86:754-760.
32. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-1098.
33. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995;86: abstr #3383.
34. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion versus amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-642.
35. Leenders AC, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infection. Br J Haem 1998;103:205-212.
36. Anaissie EJ, White MH, Uzun O, et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, #LM21. San Francisco, CA, September 18, 1995:330 (abstr).
37. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphofericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
38. White MH, Bowden RA, Sandier ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27: 296-302.
39. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haem 1997;98:711-718.
40. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340: 764-771.
41. Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-582.
42. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23:163-168.
43. Clark AD, McKendrick S, Tansey PJ, et al. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haem 1998;103: 198-204.
44. Wingard JR, White MH, Anaissie EJ, et al. A randomized double-blind comparative safety trial of AmBisome and Abelcet in febrile neutropenic patients. Focus on Fungal Infections 1999 (abstr).
45. Fleming R, Kantarjian H, Husni R, et al. Randomized study of two lipid formulations of amphotericin B in the treatment of suspected or documented fungal infections in patients with leukemia. Focus on Fungal Infections 1999 (abstr).
46. Boyle JA, Anaissie EJ. Renal sparing and increased survival related to decreased dialysis among patients treated with Abelcet (amphotericin B lipid complex). Blood 1996 (abstr).
47. Kaltenbach BL, Ross MB. Review of the lipid-based amphotericin B products. Pharmacy & Therapeutics Sept 1998:487-494.
48. Singh RM, Perdue BE. Amphotericin B: a class review. Formulary 1998;33:424-447.
49. Tollemar J, Ringden O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Safety 1995;13:207-218.
50. Persson U, Ragnarsson TG, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycosis. PharmacoEconomics 1992;2:500-508.
51. Bates DW, Yu DR, Chertow G, et al. Resource utilization and amphotericin B associated nephrotoxicity. Proceedings of ICAAC (abstr).
52. Dix SP, Wingard JR. Amphotericin B lipid complex: review of safety, pharmacokinetics, and efficacy. Drugs of Today 1996;32:411-416.
53. Ellis M, Spence D, dePauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-1412.
54. Wong-Beringer A. Criteria for use of amphotericin B lipid complex injection in adults and children. Am J Health-System Pharm 1996;53: 2751-2752.
55. Quiltz R, Arnold A, Briones G, et al. Practice guidelines for the use of lipid-based amphotericin B formulations in stem cell transplant recipients. Ann Pharmacother (in press).